<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39414273</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Impact of the COVID-19 pandemic on initiation of antihypertensive drugs in Sweden: an interrupted time series study.</ArticleTitle><Pagination><StartPage>e082209</StartPage><MedlinePgn>e082209</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e082209</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2023-082209</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Antihypertensives reduce the risk of myocardial infarction and stroke. Restrictions during the COVID-19 pandemic limited access to healthcare, which may have had a negative impact on drug prescribing. This study aimed to assess the effect of the COVID-19 pandemic on the initiation of antihypertensive drugs.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Interrupted time series study using a segmented linear regression model.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Swedish population assessed through linked national healthcare registers.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">720 300 new users of antihypertensives.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">March 2020, COVID-19 pandemic onset.</AbstractText><AbstractText Label="MAIN OUTCOMES MEASURES" NlmCategory="METHODS">The change in the initiation of antihypertensives expressed as monthly cumulative incidence, stratified by age and sex. Data on dispensed prescriptions of diuretics, beta-blockers, calcium channel blockers, ACE inhibitors (ACEi) and angiotensin receptor blockers were extracted from the Swedish Prescribed Drug Register, from March 2018 to November 2021. Initiation (new use) was defined as having no previous dispensations before March 2019. Monthly cumulative incidence in March 2019-November 2021 was calculated as the number of patients initiating each drug class in each month divided by the population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The start of the pandemic was associated with an immediate drop in the initiation of any antihypertensive, but no sustained effects were observed, as the incidence continued to increase in the postinterruption period by +0.02% each month in both sexes. The immediate drop was statistically significant for ACEi in both sexes and all antihypertensive classes except diuretics in patients &gt;65 years. А significant postintervention trend change was observed for initiation of diuretics (+0.013% overall), driven mainly by a significant increase in patients &gt;65 years. Similar findings were also observed for diuretics in females (+0.02%) and ACEi (+0.03%) in patients &gt;65 years.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The pandemic had an immediate negative short-term effect, but we found no major long-term negative influence of the COVID-19 pandemic on initiation of any type of antihypertensive drugs.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tomas</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2361-872X</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Faculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wettermark</LastName><ForeName>Bjorn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Pharmacoepidemiology &amp; Social Pharmacy, Department of Pharmacy, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0892-5668</Identifier><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajiebrahimi</LastName><ForeName>Mohammadhossein</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8118-4988</Identifier><AffiliationInfo><Affiliation>Pharmacoepidemiology &amp; Social Pharmacy, Department of Pharmacy, Uppsala University, Uppsala, Sweden hossein.hajiebrahimi@farmaci.uu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004232">Diuretics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="Y">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065186" MajorTopicYN="Y">Interrupted Time Series Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="N">Drug Prescriptions</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004232" MajorTopicYN="N">Diuretics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">EPIDEMIOLOGIC STUDIES</Keyword><Keyword MajorTopicYN="N">Hypertension</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>20</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39414273</ArticleId><ArticleId IdType="pmc">PMC11487799</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2023-082209</ArticleId><ArticleId IdType="pii">bmjopen-2023-082209</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Worl Health Organization  Coronavirus disease (covid-19) pandemic. https://www.who.int/europe/emergencies/situations/covid-19#:~:text=Cases%20of%20novel%20coronavirus%20(nCoV,pandemic%20on%2011%20March%202020 n.d. Available.</Citation></Reference><Reference><Citation>Msemburi W, Karlinsky A, Knutson V, et al. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature New Biol. 2023;613:130–7. doi: 10.1038/s41586-022-05522-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05522-2</ArticleId><ArticleId IdType="pmc">PMC9812776</ArticleId><ArticleId IdType="pubmed">36517599</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang AY, Cullen MR, Harrington RA, et al. The impact of novel coronavirus COVID-19 on noncommunicable disease patients and health systems: a review. J Intern Med. 2021;289:450–62. doi: 10.1111/joim.13184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13184</ArticleId><ArticleId IdType="pmc">PMC7675448</ArticleId><ArticleId IdType="pubmed">33020988</ArticleId></ArticleIdList></Reference><Reference><Citation>Kluge HHP, Wickramasinghe K, Rippin HL, et al. Prevention and control of non-communicable diseases in the COVID-19 response. Lancet. 2020;395:1678–80. doi: 10.1016/S0140-6736(20)31067-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31067-9</ArticleId><ArticleId IdType="pmc">PMC7211494</ArticleId><ArticleId IdType="pubmed">32401713</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223–37. doi: 10.1038/s41581-019-0244-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-019-0244-2</ArticleId><ArticleId IdType="pmc">PMC7998524</ArticleId><ArticleId IdType="pubmed">32024986</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaduganathan M, Mensah GA, Turco JV, et al. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. Washington DC: American College of Cardiology Foundation; 2022. pp. 2361–71.</Citation><ArticleIdList><ArticleId IdType="pubmed">36368511</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28:583–90. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Swamy S, Koch CA, Hannah-Shmouni F, et al. Hypertension and COVID-19: Updates from the era of vaccines and variants. J Clin Transl Endocrinol. 2022;27:100285. doi: 10.1016/j.jcte.2021.100285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcte.2021.100285</ArticleId><ArticleId IdType="pmc">PMC8645507</ArticleId><ArticleId IdType="pubmed">34900602</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth GA, Vaduganathan M, Mensah GA. Impact of the COVID-19 Pandemic on Cardiovascular Health in 2020: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;80:631–40. doi: 10.1016/j.jacc.2022.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.06.008</ArticleId><ArticleId IdType="pmc">PMC9341480</ArticleId><ArticleId IdType="pubmed">35926937</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang W-T, Toh HS, Liao C-T, et al. Cardiac Involvement of COVID-19: A Comprehensive Review. Am J Med Sci. 2021;361:14–22. doi: 10.1016/j.amjms.2020.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2020.10.002</ArticleId><ArticleId IdType="pmc">PMC7536131</ArticleId><ArticleId IdType="pubmed">33187633</ArticleId></ArticleIdList></Reference><Reference><Citation>AlShahrani I, Hosmani J, Shankar VG, et al. COVID-19 and cardiovascular system-a comprehensive review. Rev Cardiovasc Med. 2021;22:343–51. doi: 10.31083/j.rcm2202041.</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.rcm2202041</ArticleId><ArticleId IdType="pubmed">34258902</ArticleId></ArticleIdList></Reference><Reference><Citation>Tornhammar P, Jernberg T, Bergström G, et al. Association of cardiometabolic risk factors with hospitalisation or death due to COVID-19: population-based cohort study in Sweden (SCAPIS) BMJ Open. 2021;11:e051359. doi: 10.1136/bmjopen-2021-051359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-051359</ArticleId><ArticleId IdType="pmc">PMC8413466</ArticleId><ArticleId IdType="pubmed">34475186</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng M, He J, Xue Y, et al. Role of Hypertension on the Severity of COVID-19: A Review. J Cardiovasc Pharmacol. 2021;78:e648–55. doi: 10.1097/FJC.0000000000001116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FJC.0000000000001116</ArticleId><ArticleId IdType="pmc">PMC8562915</ArticleId><ArticleId IdType="pubmed">34321401</ArticleId></ArticleIdList></Reference><Reference><Citation>Azevedo RB, Botelho BG, Hollanda JVG de, et al. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021;35:4–11. doi: 10.1038/s41371-020-0387-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41371-020-0387-4</ArticleId><ArticleId IdType="pmc">PMC7384729</ArticleId><ArticleId IdType="pubmed">32719447</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A, Chen S, Pasea L, et al. Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. Eur J Prev Cardiol. 2021;28:1599–609. doi: 10.1093/eurjpc/zwaa155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjpc/zwaa155</ArticleId><ArticleId IdType="pmc">PMC7928969</ArticleId><ArticleId IdType="pubmed">33611594</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogueira RG, Qureshi MM, Abdalkader M, et al. Global Impact of COVID-19 on Stroke Care and IV Thrombolysis. Neurology (ECronicon) 2021;96:e2824–38. doi: 10.1212/WNL.0000000000011885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011885</ArticleId><ArticleId IdType="pmc">PMC8205458</ArticleId><ArticleId IdType="pubmed">33766997</ArticleId></ArticleIdList></Reference><Reference><Citation>Mafham MM, Spata E, Goldacre R, et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. The Lancet. 2020;396:381–9. doi: 10.1016/S0140-6736(20)31356-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31356-8</ArticleId><ArticleId IdType="pmc">PMC7429983</ArticleId><ArticleId IdType="pubmed">32679111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempers EK, Chen Q, Visser C, et al. Changes in incidence of hospitalization for cardiovascular diseases during the COVID-19 pandemic in The Netherlands in 2020. Sci Rep. 2023;13:12832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10409797</ArticleId><ArticleId IdType="pubmed">37553430</ArticleId></ArticleIdList></Reference><Reference><Citation>Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi: 10.1136/bmj.b1665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b1665</ArticleId><ArticleId IdType="pmc">PMC2684577</ArticleId><ArticleId IdType="pubmed">19454737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurdi A, Mueller T, Weir N. An umbrella review and meta-analysis of renin-angiotensin system drugs use and COVID-19 outcomes. Eur J Clin Invest. 2023;53:e13888. doi: 10.1111/eci.13888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13888</ArticleId><ArticleId IdType="pmc">PMC9874890</ArticleId><ArticleId IdType="pubmed">36205627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605–10. doi: 10.1161/CIRCULATIONAHA.104.510461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.104.510461</ArticleId><ArticleId IdType="pubmed">15897343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970–6. doi: 10.1161/01.HYP.0000124667.34652.1a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000124667.34652.1a</ArticleId><ArticleId IdType="pubmed">15007027</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezabih YM, Bezabih A, Alamneh E, et al. Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes. BMC Infect Dis. 2021;21:527. doi: 10.1186/s12879-021-06088-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06088-6</ArticleId><ArticleId IdType="pmc">PMC8178664</ArticleId><ArticleId IdType="pubmed">34090358</ArticleId></ArticleIdList></Reference><Reference><Citation>Loader J, Lampa E, Gustafsson S, et al. Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19. J Am Heart Assoc. 2021;10:e021154. doi: 10.1161/JAHA.120.021154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.021154</ArticleId><ArticleId IdType="pmc">PMC8475700</ArticleId><ArticleId IdType="pubmed">34320843</ArticleId></ArticleIdList></Reference><Reference><Citation>Baral R, Tsampasian V, Debski M, et al. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021;4:e213594. doi: 10.1001/jamanetworkopen.2021.3594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.3594</ArticleId><ArticleId IdType="pmc">PMC8013817</ArticleId><ArticleId IdType="pubmed">33787911</ArticleId></ArticleIdList></Reference><Reference><Citation>Patoulias D, Katsimardou A, Stavropoulos K, et al. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities Curr Hypertens Rep. 2020;22 doi: 10.1007/s11906-020-01101-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-020-01101-w</ArticleId><ArticleId IdType="pmc">PMC7481766</ArticleId><ArticleId IdType="pubmed">32910274</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, Zhu Y, Hong Y. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis. Hypertension. 2020;76:e13–4. doi: 10.1161/HYPERTENSIONAHA.120.15572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.15572</ArticleId><ArticleId IdType="pubmed">32458694</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnanenthiran SR, Borghi C, Burger D, et al. Renin‐Angiotensin System Inhibitors in Patients With COVID‐19: A Meta‐Analysis of Randomized Controlled Trials Led by the International Society of Hypertension. JAHA. 2022;11 doi: 10.1161/JAHA.122.026143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.122.026143</ArticleId><ArticleId IdType="pmc">PMC9496439</ArticleId><ArticleId IdType="pubmed">36000426</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren L, Yu S, Xu W, et al. Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis. J Cardiol. 2021;77:482–91. doi: 10.1016/j.jjcc.2020.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2020.10.015</ArticleId><ArticleId IdType="pmc">PMC7605745</ArticleId><ArticleId IdType="pubmed">33168337</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez SR, Frank RC, Stevenson EK, et al. Dihydropyridine Calcium Channel Blockers and the Risk of Severe COVID-19. Chest. 2021;160:89–93. doi: 10.1016/j.chest.2021.01.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.01.073</ArticleId><ArticleId IdType="pmc">PMC7857077</ArticleId><ArticleId IdType="pubmed">33548220</ArticleId></ArticleIdList></Reference><Reference><Citation>Crespi B, Alcock J. Conflicts over calcium and the treatment of COVID-19. Evol Med Public Health. 2021;9:149–56. doi: 10.1093/emph/eoaa046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emph/eoaa046</ArticleId><ArticleId IdType="pmc">PMC7717197</ArticleId><ArticleId IdType="pubmed">33732462</ArticleId></ArticleIdList></Reference><Reference><Citation>Kow CS, Ramachandram DS, Hasan SS. Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers: a systematic review and meta-analysis. Hypertens Res. 2022;45:360–3. doi: 10.1038/s41440-021-00786-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-021-00786-z</ArticleId><ArticleId IdType="pmc">PMC8576454</ArticleId><ArticleId IdType="pubmed">34754084</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsagaff MY, Mulia EPB, Maghfirah I, et al. Association of calcium channel blocker use with clinical outcome of COVID-19: A meta-analysis. Diabetes Metab Syndr. 2021;15:102210. doi: 10.1016/j.dsx.2021.102210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.102210</ArticleId><ArticleId IdType="pmc">PMC8282943</ArticleId><ArticleId IdType="pubmed">34298269</ArticleId></ArticleIdList></Reference><Reference><Citation>Mousa SI, Nyberg F, Hajiebrahimi M, et al. Initiation of antihypertensive drugs to patients with confirmed COVID-19-A population-based cohort study in Sweden. Basic Clin Pharmacol Toxicol. 2022;131:196–204. doi: 10.1111/bcpt.13766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcpt.13766</ArticleId><ArticleId IdType="pmc">PMC9349802</ArticleId><ArticleId IdType="pubmed">35726121</ArticleId></ArticleIdList></Reference><Reference><Citation>Janlöv N, Blume S, Glenngård AH, et al.   Sweden: Health System Summary, 2023. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies; 2023. https://eurohealthobservatory.who.int/publications/i/sweden-health-system-summary Available.</Citation></Reference><Reference><Citation>Nyberg F, Franzén S, Lindh M, et al. Swedish Covid-19 Investigation for Future Insights - A Population Epidemiology Approach Using Register Linkage (SCIFI-PEARL) Clin Epidemiol. 2021;13:649–59. doi: 10.2147/CLEP.S312742.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S312742</ArticleId><ArticleId IdType="pmc">PMC8331198</ArticleId><ArticleId IdType="pubmed">34354377</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24:659–67. doi: 10.1007/s10654-009-9350-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-009-9350-y</ArticleId><ArticleId IdType="pmc">PMC2773709</ArticleId><ArticleId IdType="pubmed">19504049</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson JF, Svedberg P, Olén O, et al. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol. 2019;34:423–37. doi: 10.1007/s10654-019-00511-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-019-00511-8</ArticleId><ArticleId IdType="pmc">PMC6451717</ArticleId><ArticleId IdType="pubmed">30929112</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallerstedt SM, Wettermark B, Hoffmann M. The First Decade with the Swedish Prescribed Drug Register - A Systematic Review of the Output in the Scientific Literature. Basic Clin Pharmacol Toxicol. 2016;119:464–9. doi: 10.1111/bcpt.12613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcpt.12613</ArticleId><ArticleId IdType="pubmed">27112967</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson JF. The first eight months of Sweden’s COVID-19 strategy and the key actions and actors that were involved. Acta Paediatr. 2020;109:2459–71. doi: 10.1111/apa.15582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15582</ArticleId><ArticleId IdType="pmc">PMC7537539</ArticleId><ArticleId IdType="pubmed">32951258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson JF. How Sweden approached the COVID-19 pandemic: Summary and commentary on the National Commission Inquiry. Acta Paediatr. 2023;112:19–33. doi: 10.1111/apa.16535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.16535</ArticleId><ArticleId IdType="pmc">PMC9538368</ArticleId><ArticleId IdType="pubmed">36065136</ArticleId></ArticleIdList></Reference><Reference><Citation>Olofsson T, Vilhelmsson A. Dataset: COVID-19 epidemic policy and events timeline (Sweden) Data Brief. 2022;40:107698. doi: 10.1016/j.dib.2021.107698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dib.2021.107698</ArticleId><ArticleId IdType="pmc">PMC8667349</ArticleId><ArticleId IdType="pubmed">34926743</ArticleId></ArticleIdList></Reference><Reference><Citation>Caswell JM. Interrupted time series analysis for single series and comparative designs: a guide for beginners with sas macro. 2019. https://www.academia.edu/35275583/Interrupted_Time_Series_Analysis_for_Single_Series_and_Comparative_Designs_A_Guide_for_Beginners_with_SAS_Macro?sm=b Available.</Citation></Reference><Reference><Citation>Turner SL, Karahalios A, Forbes AB, et al. Creating effective interrupted time series graphs: Review and recommendations. Res Synth Methods. 2021;12:106–17. doi: 10.1002/jrsm.1435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1435</ArticleId><ArticleId IdType="pmc">PMC7818488</ArticleId><ArticleId IdType="pubmed">32657532</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr MJ, Wright AK, Leelarathna L, et al. Impact of COVID-19 restrictions on diabetes health checks and prescribing for people with type 2 diabetes: a UK-wide cohort study involving 618 161 people in primary care. BMJ Qual Saf. 2022;31:503–14. doi: 10.1136/bmjqs-2021-013613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjqs-2021-013613</ArticleId><ArticleId IdType="pmc">PMC8520602</ArticleId><ArticleId IdType="pubmed">34642228</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale CE, Takhar R, Carragher R, et al. The impact of the COVID-19 pandemic on cardiovascular disease prevention and management. Nat Med. 2023;29:219–25. doi: 10.1038/s41591-022-02158-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02158-7</ArticleId><ArticleId IdType="pubmed">36658423</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson P, Nakitanda AO, Löfling L, et al. Patterns of prescription dispensation and over-the-counter medication sales in Sweden during the COVID-19 pandemic. PLoS ONE. 2021;16:e0253944. doi: 10.1371/journal.pone.0253944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0253944</ArticleId><ArticleId IdType="pmc">PMC8362980</ArticleId><ArticleId IdType="pubmed">34388166</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffin LJ, Kaufman HW, Chen Z, et al. Rise in Blood Pressure Observed Among US Adults During the COVID-19 Pandemic. Circulation. 2022;145:235–7. doi: 10.1161/CIRCULATIONAHA.121.057075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.057075</ArticleId><ArticleId IdType="pmc">PMC8763044</ArticleId><ArticleId IdType="pubmed">34865499</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummel B, Yerkes MA, Harskamp RE, et al. The COVID-19 pandemic and temporal change in metabolic risk factors for cardiovascular disease: A natural experiment within the HELIUS study. SSM Popul Health. 2023;23:101432. doi: 10.1016/j.ssmph.2023.101432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ssmph.2023.101432</ArticleId><ArticleId IdType="pmc">PMC10195766</ArticleId><ArticleId IdType="pubmed">37234865</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah NP, Clare RM, Chiswell K, et al. Trends of blood pressure control in the U.S. during the COVID-19 pandemic. Am Heart J. 2022;247:15–23. doi: 10.1016/j.ahj.2021.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2021.11.017</ArticleId><ArticleId IdType="pmc">PMC8662834</ArticleId><ArticleId IdType="pubmed">34902314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020;80:639–45. doi: 10.1016/j.jinf.2020.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.019</ArticleId><ArticleId IdType="pmc">PMC7118526</ArticleId><ArticleId IdType="pubmed">32240670</ArticleId></ArticleIdList></Reference><Reference><Citation>Myhre PL, Heck SL, Skranes JB, et al. Cardiac pathology 6 months after hospitalization for COVID-19 and association with the acute disease severity. Am Heart J. 2021;242:61–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8363180</ArticleId><ArticleId IdType="pubmed">34400140</ArticleId></ArticleIdList></Reference><Reference><Citation>Karadavut S, Altintop I. Long-term cardiovascular adverse events in very elderly COVID-19 patients. Arch Gerontol Geriatr. 2022;100:104628. doi: 10.1016/j.archger.2022.104628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archger.2022.104628</ArticleId><ArticleId IdType="pmc">PMC8783397</ArticleId><ArticleId IdType="pubmed">35091302</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang V, Fisher M, Hou W, et al. Incidence of New-Onset Hypertension Post-COVID-19: Comparison With Influenza. Hypertension. 2023;80:2135–48. doi: 10.1161/HYPERTENSIONAHA.123.21174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.123.21174</ArticleId><ArticleId IdType="pubmed">37602375</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>